Related Research Articles
The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.
Mertansine, also called DM1, is a thiol-containing maytansinoid that for therapeutic purposes is attached to a monoclonal antibody through reaction of the thiol group with a linker structure to create an antibody-drug conjugate (ADC).
Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator.
Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.
Varlilumab is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.
Lifastuzumab vedotin is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.
Sofituzumab vedotin is a monoclonal antibody designed for the treatment of ovarian cancer.
Brontictuzumab is a humanized monoclonal antibody designed for the treatment of cancer.
Lumretuzumab is a humanized monoclonal antibody designed for the treatment of cancer.
Vanucizumab is an experimental humanized monoclonal antibody designed for the treatment of cancer.
Vandortuzumab vedotin is a humanized monoclonal antibody designed for the treatment of cancer.
Depatuxizumab mafodotin is an antibody-drug conjugate designed for the treatment of cancer. It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.
Duvortuxizumab (INN) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.
Oleclumab is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.
Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
Pamrevlumab is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.
Andecaliximab is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
Cofetuzumab pelidotin is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.
References
- ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association .
- ↑ Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y (August 2022). "Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?". Biomedicines. 10 (9): 2113. doi: 10.3390/biomedicines10092113 . PMC 9495728 . PMID 36140214.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |